Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy

Coagulation Therapy in Hemophilia A and its Relation to Factor VIII Inhibitor in Northeast of Iran

Detection of Factor VIII Inhibitors in Hemophilia A Patients

Background: Factor VIII administration to hemophilia A patients results in an immune response (inhibitor formation) which significantly complicates the therapy. The present study was performed to determine the prevalence of inhibitor development in hemophilia A patients receiving recombinant factor VIII therapy. Materials and Methods: This was an observational descriptive study. Clotting fac...

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.

Current management of hemophilia A includes prophylaxis with factor VIII (FVIII) replacement every 2 to 3 days. BAX 855, Baxalta's pegylated full-length recombinant FVIII (rFVIII), was designed to increase half-life and, thus, reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy. BAX 855 was evaluated in previously treated patients with severe hemophilia A who we...

coagulation therapy in hemophilia a and its relation to factor viii inhibitor in northeast of iran

0

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy

Postpartum-acquired hemophilia A is a rare and potentially severe complication of pregnancy caused by an autoantibody against factor VIII [1]. Acquired factor VIII deficiency is associated with autoimmune conditions, neoplastic diseases, drug hypersensitivity, and pregnancy. A retrospective study analyzed 51 published cases of postpartum factor VIII inhibitors, with regard to the outcome accord...